Epidemic Keratoconjunctivitis Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Epidemic Keratoconjunctivitis Market is Segmented By Medication (Dexamethasone, Fluorometholone, Ophthalmic Prednisolone, Rimexolone 1%, Cidofovir, 2% Povidone-iodine), By Route of Administration (Topical, Oral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Epidemic Keratoconjunctivitis Market Overview

Global Epidemic Keratoconjunctivitis Market reached US$ YY billion in 2023 and is expected to reach US$ YY  million by 2031 growing at a CAGR of YY% during the forecast period 2024-2031.

Epidemic keratoconjunctivitis also known as adenoviral keratoconjunctivitis is a contagious eye infection, a type of adenovirus disease caused by adenoviruses. It typically presents as conjunctivitis with a sudden onset of a painful red eye, and watery discharge.

The type 8 and 37 adenoviruses are the most prevalent cause. They can spread by contaminated eye inspection tools and eye treatments, contact with diseased eyes, poorly chlorinated swimming pools, and other contaminated things. Corneal scarring occurs in up to half of cases and the blurred vision can continue for a long time in some people.

Epidemic Keratoconjunctivitis Market Scope

For more details on this report – Request for Sample 

Epidemic Keratoconjunctivitis Market Market Dynamics

The increasing burden of viral conjunctivitis

The increasing burden of viral conjunctivitis acts as a significant driver for market growth. Epidemic keratoconjunctivitis (EKC) is a highly contagious form of viral conjunctivitis that develops corneal inflammation.

Conjunctivitis is one of the most common causes of red-eye and affects patients of all ages and socioeconomic classes. Viral conjunctivitis is responsible for the majority of infectious conjunctivitis, accounting for up to 75% of cases.

Additionally, an estimated 90% of cases of viral conjunctivitis are brought on by adenoviruses. Children with pharyngoconjunctival fever (PCF) caused by HAdV types 3, 4, and 7 experience fever, pharyngitis, and periauricular lymphadenopathy in addition to acute follicular conjunctivitis.

Also, according to the National Institute of Health Reports, between 6% and 60% of instances of infectious conjunctivitis are caused by EKC. It was discovered that 8% of patients presenting to an eye clinic's emergency room had EKC. Hence, EKC is the most prevalent viral eye illness and results in significant financial losses since it prevents people from working.

Furthermore, significant growth drivers such as the growing awareness of epidemic keratoconjunctivitis, and increasing clinical trials for treatment drugs are expected to drive the market in the forecast period.

Side effects associated with treatment drugs

Treatment drugs such as dexamethasone eye drops are used to treat inflammation of the eyes caused by allergies and certain conditions. This particular drug can cause blurred vision, redness of the eyes, throbbing pain of the eye, and itching of the eyes. Hence, the above factors are expected to hamper the market growth.

Epidemic Keratoconjunctivitis Market Segment Analysis

The global epidemic keratoconjunctivitis market is segmented based on medication, route of administration, distribution channel and region.

Medication accounted for approximately 42.5% of the market share 

Epidemic keratoconjunctivitis (EKC) is a viral conjunctivitis caused by a group of adenoviruses. Epidemic keratoconjunctivitis is highly contagious and has a tendency to occur in epidemics. Medications are expected to hold the largest market share over the period forecast.

Treatment is mostly symptomatic (cold compresses and artificial tears). Antiviral (cidofovir ) and cyclosporine eye drops were tried in some patients. Topical corticosteroids are often prescribed in severe cases and while they do assist in reducing inflammatory symptoms, they do not significantly reduce recovery time.

It has been demonstrated that cidofovir can shorten the viral replication cycle and is useful as a preventative measure. One of the most effective topical antiviral medications for treating and preventing epidemic keratoconjunctivitis may be cidofovir.

Global Epidemic Keratoconjunctivitis Market Geographical Share

North America is expected to hold a significant position in the global epidemic keratoconjunctivitis market share

The global epidemic keratoconjunctivitis market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. 

North America has maintained a significant market proportion due to factors such as the rising prevalence of epidemic keratoconjunctivitis, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.

For instance, the incidence of viral conjunctivitis is approximately 80,000 per 100,000 cases with acute conjunctivitis. The incidence of viral conjunctivitis caused by adenoviruses approximately ranges from 65,000 to 90,000 cases per 100,000 cases with viral conjunctivitis.

COVID-19 Impact Analysis 

The COVID-19 pandemic has had a significant impact on the global epidemic keratoconjunctivitis treatment market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, drug launches, and consultations worldwide. 

With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the epidemic keratoconjunctivitis treatment market is expected to be moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include Sandoz Group AG, Xenon Pharmaceuticals Inc, Bausch + Lomb Corp, Rayner Group, AdvaCare Pharma, Eyeris Vision Care Pvt. Ltd., AbbVie Inc., Alcon AG, Viatris Inc., Aspen Pharmacare Holdings Limited among others.

Key Developments

• In July 2023, Harrow acquired Santen’s branded ophthalmic portfolio that includes U.S. and Canadian Commercial Rights to FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, ZERVIATE, and Non-Prescription Brands FRESHKOTE and Cationorm PLUS. 

Why Purchase the Report?

• To visualize the global epidemic keratoconjunctivitis market segmentation based on medication, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of epidemic keratoconjunctivitis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global epidemic keratoconjunctivitis treatment market report would provide approximately 61 tables, 63 figures, and 185 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies